Home
|
Glossary
|
Site Map
|
Contact Us
about us
product pipeline
technology
clinical trials
investors & news
careers
•
Management
•
Board of Directors
•
Collaborations
•
Brentuximab Vedotin (SGN-35)
•
Lintuzumab (SGN-33)
•
Dacetuzumab (SGN-40)
•
SGN-70
•
SGN-75
•
Preclinical Programs
•
Scientific Publications
•
ADC Technology
•
SEA Technology
•
Scientific Publications
By Program:
•
Brentuximab Vedotin (SGN-35)
•
Lintuzumab (SGN-33)
•
Dacetuzumab (SGN-40)
•
SGN-70
•
SGN-75
By Indication:
•
Hodgkin Lymphoma
•
Non-Hodgkin Lymphoma
•
Multiple Myeloma
•
Leukemia/MDS
•
Autoimmune
•
Solid Tumors
•
Press Releases
•
Stock Performance
•
SEC Filings
•
Webcasts & Events
•
Scientific Publications
•
Corporate Governance
•
Analyst Coverage
•
Financial Reports
•
Investor FAQ
•
Information Request
•
Benefits
•
Living in the Area
•
Job Opportunities
INVESTORS & NEWS
•
Press Releases
•
Stock Performance
•
SEC Filings
•
Webcasts & Events
•
Scientific Publications
•
Corporate Governance
•
Analyst Coverage
•
Financial Reports
•
Investor FAQ
•
Information Request
Oppenheimer & Co. Healthcare Conference
Tuesday, November 3, 2009
2:10 p.m. ET
Webcast Presentation
Help
Click here for webcast
Event Details
Title
Oppenheimer & Co. Healthcare Conference
Date and Time
Tuesday, November 3, 2009
2:10 p.m. ET
Duration
30 Minutes
Location
New York
, NY
Download the
Windows Media Player
or
Real Player
plug-in in order to listen to the webcast.
Unauthorized recording or downloading of this event is not permitted.
© Copyright 2009 Thomson Reuters . All rights reserved.